The current situation with regard to human melanoma and genetic inferences

Current Opinion in Oncology

Volumn 8, Issue 2, 1996, Pages 136-142

  Hayward, Nicholas K ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLIN DEPENDENT KINASE; MUTANT PROTEIN;

CANCER SUSCEPTIBILITY; CELL CYCLE; CHROMOSOME 9P; DYSPLASTIC NEVUS; ENVIRONMENTAL FACTOR; GENE LOCUS; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; SOLAR RADIATION; TUMOR SUPPRESSOR GENE;

EID: 0029947139     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199603000-00011     Document Type: Review

References (69)

1. Greene MH, Goldin LR, Clark WH, Lovrien E, Kraemer KH, Tucker MA, Elder DE, Fraser MC, Rowe S: Familial cutaneous melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A 1983, 80:6071-6075.
2. Bale S, Dracopoli N, Tucker M, Clark W, Fraser M, Stanger B, Green P, Donis-Keller H, Holman D, Greene M: Mapping the gene for hereditary cutaneous melanoma-dysplastic naevus to chromosome 1p. N Engl J Med 1989, 320:1367-1372.
3. Goldstein AM, Bale SJ, Tucker MA: Linkage analysis of melanoma alone and chromosome 1p markers PND, D1S47, and LMYC. Cytogenet Cell Genet 1992, 59:203-205.
4. Gruis N, Bergman W, Frants R: Locus for susceptibility to melanoma on chromosome 1p. N Engl J Med 1990, 322:853-854.
5. Cannon-Albright L, Goldgar D, Wright E, Turco A, Jost M, Meyer L, Piepkorn M, Zone J, Skolnick M: Evidence against the reported linkage of cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. Am J Hum Genet 1990, 46:912-918.
6. Nancarrow DJ, Palmer JM, Walters MK, Kerr B, Hafner G, Garske L, McLeod G, Hayward N: Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 regions of chromosome arm 1p in 7 Australian families. Genomics 1992, 12:18-25.
7. Kefford R, Salmon J, Shaw H, Donald J, McCarthy W: Hereditary melanoma in Australia: variable association with dysplastic naevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 1991, 51:45-55.
8. Nancarrow DJ, Walker GJ, Weber JL, Walters M, Palmer J, Hayward N: Linkage mapping of melanoma (MLM) using 172 microsatellite markers. Genomics 1992, 14:939-947.
9. Gruis N, Sandkuijl L, Weber J, Van der Zee A, Borgstein A-M, Bergman W, Frants R: Linkage analysis in Dutch familial atypical mole-melanoma (FAMMM) syndrome families: effect of naevus count. Melanoma Res 1993, 3:271-277.
10. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlok DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE, Dracopoli NC: Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992, 89:10557-10561.
11. Petty EM, Gibson LH, Fountain JW, Bolognia JL, Yang-Feng TL, Housman DE, Bale AE: Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). Am J Hum Genet 1993, 53:96-104.
12. Cannon-Albright L, Goldgar DE, Meyer LJ, Lewis C, Anderson D, Fountain J, Hegi M, Wiseman R, Petty E, Bale A, Olopade O, Diaz M, Kwiatkowski D, Piepkorn M, Zone J, Skolnick M: Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992, 258:1148-1152.
13. Nancarrow D, Mann G, Holland E, Walker G, Beaton S, Walters M, Luxford C, Palmer J, Donald J, Weber J, Fountain J, Kefford R, Hayward N: Confirmation of chromosome 9p linkage to melanoma. Am J Hum Genet 1993, 53:936-942.
14. MacGeoch C, Newton-Bishop JA, Bataille V, Bishop DT, Frischauf A-M, Melon R, Cuzick J, Pinney E, Spurr N: Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 1994, 3:2195-2200.
15. Goldstein A, Dracopoli N, Engelstein M, Fraser M, Clark WH Jr, Tucker M: Linkage of cutaneous malignant melanoma/dysptastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 1994, 54:489-496.
16. Goldstein A, Dracopoli N, Ho E, Fraser M, Kearns K, Bale S, McBride O, Clark W, Tucker M: Further evidence for a locus for cutaneous malignant melanoma-dysplastic naevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 1993, 52:537-550.
17. Weaver-Feldhaus JM, Gruis NA, Neuhausen S, Le Paslier D, Stockert E, Skolnick MH, Kamb A: Localization of a putative tumour suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci U S A 1994, 91:7563-7567.
18. Cannon-Albright LA, Goldgar DE, Neuhausen S, Gruis NA, Anderson DE, Lewis CM, Jost M, Tran TD, Nyguen K, Kamb A, Weaver-Feldhaus JM, Meyer L, Zone JJ, Skolnick M: Localisation of the 9p melanoma susceptiblity locus (MLM) to a 2-cm region between D9S736 and D9S171. Genomics 1994, 23: 265-268.
19. Nobori T, Miura K, Wu DJ, Louis A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756.
20. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
21. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
22. Elledgs S, Harper JW: Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 1994, 6:847-852.
23. Grana X, Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995, 11:211-219.
24. Sherr C, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163.
25. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994, 8:27-32.
26. Mori T, Miura K, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinomas. Cancer Res 1994, 54:3396-3397.
27. Zhou X, Tarmin L, Yin J, Jiang H-Y, Suzuki H, Rhyu M-G, Abraham JM, Meltzer SJ: The MTS1 gene is frequently mutated in primary human esophageal tumours. Oncogene 1994, 9:3737-3741.
28. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T, Terada M: Mutation frequency of the p16/CDKN2 gene in primary cancer in the upper digestive tract. Cancer Res 1995, 55:3421-3423.
29. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T, Takahashi T: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995, 55:514-517.
30. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y: Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 1994, 202:1426-1430.
31. INK4B/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995, 55:1448-1451.
32. Giani C, Finocchiaro G: Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994, 54:6338-6339.
33. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994, 54:6321-6324.
34. Pollock PM, Yu F, Qiu L, Parsons PG, Hayward NK: Evidence for UV induction of CDKN2 mutations in melanoma cell lines. Oncogene 1995, 11:663-668. CDKN2 mutations from melanoma cell lines showed patterns characteristic of ultraviolet-induced mutagenesis.
35. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, Huebner K: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4, in melanoma. Cancer Res 1994, 54:5269-5272. The authors identified a germline mutation of CDKN2 in one of 10 individuals with familial melanoma. Somatic mutations were also found in six melanoma cell lines, but mutations were not found in 13 metastatic cutaneous melanomas and 17 primary ocular melanomas.
36. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A: CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995, 10:1061-1067. CDKN2 mutations from melanoma cell lines showed patterns characteristic of ultraviolet-induced mutagenesis.
37. Gruis NA, Weaver-Feldhaus JM, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres E, Skolnick M, Cordon-Cardo C, Kamb A: Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995, 146:1199-1206. First paper to show that CDKN2 mutations occurred in a small proportion (five of 34) of fresh melanomas and that these changes were characteristic of ultraviolet-induced mutagenesis.
38. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Pointen J: A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991, 88:10124-10128.
39. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nature Genef 1994, 8:15-21. A seminal paper describing germline mutations of CDKN2 in familial melanoma patients. There was a lack of correlation observed between mutation carriers and the occurrence of dysplastic nevi.
40. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994, 8:22-26. A seminal paper describing germline mutations of CDKN2 in familial melanoma patients.
41. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR: CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 1995, 5:169-177. This report found several individuals within the Dutch melanoma kindreds that had all the hallmarks of the familial atypical multiple-mole melanoma syndrome yet were not mutant haplotype carriers, thus indicating that genes other than CDKN2 are involved in predisposition to multiple atypical moles (dysplastic nevus syndrome).
42. Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, Hogg D: Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995, 11:405-412. Identification of a germline CDKN2 mutation in a Canadian family that encodes a functionally abnormal protein.
43. Caims P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumours with 9p loss. Science 1994, 265:415-416.
44. Spruck CH III, Gonzalez-Zuleta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA: p16 Gene in uncultured tumours. Nature 1994, 370:183-184.
45. INK4 in human cancer. Proc Natl Acad Sci U S A 1994, 91:11045-11049.
46. INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1996, 10:1845-1852. Identification of six novel germline mutations of CDKN2 in Australian melanoma families.
47. INK4 function. Nature Genet 1995, 10:114-116. This paper shows that several mutants of p16 derived from familial melanoma cases or tumors are functionally compromised, whereas polymorphic variants are not.
48. INK4a tumour suppressor protein. Cancer Res 1995, 55:2503-2506. This paper shows that certain mutants of p16 derived from tumors as well as one familial melanoma-specific mutant are functionally compromised, whereas some tumour-specific variants are not.
49. Koh J, Enders GH, Dynlacht BD, Harlow E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995, 375:506-510. This papers shows that several mutants of p16 derived from tumors or familial melanoma cases are functionally compromised, whereas polymorphic variants are not.
50. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995, 375:503-506. This paper shows that wild-type p16 arrests normal cell in G1 but a tumor-derived mutant of p16 does not.
51. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 1995, 10:351-353. A description of two individuals with both alleles of CDKN2 inactivated in their germline. One of these patients failed to develop melanoma prior to her death at 55 years of age, indicating that lack of p16 alone is not sufficient for melanoma development.
52. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
53. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
54. Cannon-Albright LA, Meyer L, Goldgar DE, Lewis CM, McWhorter WP, Jost M, Harrison D, Anderson DE, Zone JJ, Skolnick MH: Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 1994, 54:6041-6044. An analysis of 124 gene carriers in three 9p-linked melanoma families showed that carriers had higher total nevus densities and total nevus counts than noncarriers. Among gene carriers there was a correlation between melanoma development and fair skin type as well as higher cumulative sunlight exposure.
55. Battistutta D, Palmer JM, Walters MK, Walker GJ, Nancarrow DJ, Hayward NK: Incidence of familial melanoma and MLM2 gene. Lancet 1994, 344:1607-1608. This study presents data to support an increasing phenotypic penetrance of CDKN2 mutations in familial melanoma cases from more recent birth cohorts. These findings are consistent with an increase in sunlight exposure due to lifestyle changes.
56. Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM: Systemic cancer and the FAMMM syndrome. Br J Cancer 1990, 61:932-936.
57. Lynch HT, Fusaro RM, Pester J, Oosterhuis JA, Went LN, Rumke P, Neering H, Lynch JF: Tumour spectrum in the FAMMM syndrome. Br J Cancer 1981, 44:553-560.
58. INK4B Is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994, 371:257-261.
59. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A: Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene 1995, 11:987-991. No mutations of the p15 gene were found in six melanoma families that were linked to 9p but did not have mutations within the CDKN2 coding region. Analysis of the p15 gene in 58 tumor cell lines of diverse origins also did not identify any mutations.
60. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 1995, 55:2988-2994. Description of an additional alternatively spliced exon (1β) in the CDKN2 gene whose expression appears to be tissue specific and cell cycle stage specific. Analysis of this exon in 24 tumor cell lines and six melanoma kindreds did not identify any mutations.
61. INK4A transcript. Cancer Res 1995, 55:2995-2997. Description of an additional alternatively spliced exon (1β) in the CDKN2 gene. Analysis of this exon in eight tumor cell lines and 50 primary tumors did not identify any mutations.
62. INK4B/MTS2-related CDK6 inhibitor correlates with wild-type pRb function. Genes Dev 1994, 8:2939-2952.
63. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
64. Walker GJ, Nancarrow DJ, Walters MK, Palmer JM, Weber J, Hayward NK: Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer 1994, 59:771-775.
65. Vidal MJ, Loganzo F, de Oliveira AR, Hayward NK, Albino AP: Mutations and defective expression of the WAF1 p21 tumour suppressor gene in malignant melanomas. Melanoma Res 1996, 5:243-250. Lack of germline mutations of the gene encoding the CDK-inhibitor p21 in seven Australian melanoma kindreds.
66. Klp1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995, 55:1211-1214.
67. Demetrick DJ, Zhang H, Beach DH: Chromosomal mapping of human CDK2, CDK4 and CDK6 cell cycle kinase genes. Cytogenel Cell Genet 1994, 66:72-74.
68. Walker GJ, Palmer JM, Walters MK, Hayward NK: A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer 1995, 12:134-141. Mini-allelotype study of regions of loss of somatic heterozygosity in melanoma. Review of melanoma-specific loss of somatic heterozygosity and karyotypic abnormalities and presentation of a genetic model for melanoma development.
69. Healey E, Rehman I, Angus B, Rees JL: Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosom Cancer 1995, 12:152-156. A mini-allelotype study of regions of loss of somatic heterozygosity in melanoma.